# Chlorella Cholesterol Meta-analysis: What the Evidence Says
Canonical: https://www.migaku.app/guides/chlorella-cholesterol-meta-analysis-evidence-review
Category: evidence-review
Summary: Chlorella Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are sys
Last reviewed: 2026-07-09
Reviewed by: Migaku Evidence Review
# Chlorella Cholesterol Meta-analysis: What the Evidence Says

## Quick Answer

Chlorella Cholesterol Meta-analysis has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 2 systematic review.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Does Chlorella Supplementation Improve Adiposity, Metabolic Dysfunction, and Oxidative Stress in Individuals With Excess Weight? A Systematic Review and Meta‐Analysis | systematic review | 1 | 2026-04-22 | 10.1002/fsn3.71715 |
| The beneficial effects of Chlorella vulgaris supplementation on health-related indices in patients with non-alcoholic fatty liver disease: a GRADE-assessed systematic review and meta-analysis | systematic review | 1 | 2026-02-07 | 10.1186/s12872-025-05433-w |

## What The Sources Report

- It significantly elevates the risk of numerous chronic conditions, including cardiovascular diseases (CVD), type 2 diabetes (T2DM), osteoarthritis, and certain cancers, often leading to premature mortality (Safaei et al. ; Khani et al. ; Zhang et al. ; Hutten et al. ). [Jafari Ali (2026); evidence level 1]
- However, most available medications are synthetic, often costly, and associated with adverse side effects (Arterburn et al. ; Liu et al. ). [Jafari Ali (2026); evidence level 1]
- Non-alcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), represents a spectrum of metabolic disorders characterized by excessive fat accumulation in the liver, affecting more than 5% of hepatocytes. [Jafari Ali (2026); evidence level 1]
- A significant proportion of NAFLD patients exhibit features of metabolic syndrome, including insulin resistance, dyslipidemia, hypertension, and obesity, all of which substantially increase the risk of cardiovascular disease (CVD). [Jafari Ali (2026); evidence level 1]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. For chlorella cholesterol meta-analysis, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Jafari Ali (2026). Does Chlorella Supplementation Improve Adiposity, Metabolic Dysfunction, and Oxidative Stress in Individuals With Excess Weight? A Systematic Review and Meta‐Analysis. DOI: 10.1002/fsn3.71715. PMCID: PMC13100651. PMID: 42027804. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13100651/
- Jafari Ali (2026). The beneficial effects of Chlorella vulgaris supplementation on health-related indices in patients with non-alcoholic fatty liver disease: a GRADE-assessed systematic review and meta-analysis. DOI: 10.1186/s12872-025-05433-w. PMCID: PMC12977676. PMID: 41652544. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC12977676/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.